NewGenIvf Prices $1.25 Million Public Offering on Nasdaq
NewGenIvf Group Limited announced pricing of a best-efforts public offering expected to raise roughly $1.25 million before fees.
NewGenIvf Group Limited, the Nasdaq-listed company trading under the ticker NIVF, announced on Sept. 29, 2026, the pricing of a public offering it expects to generate approximately $1.25 million in gross proceeds before placement agent fees and other offering-related expenses are deducted.
The offering is being conducted on a reasonable best-efforts basis, meaning the placement agent is not obligated to purchase any shares outright but will work to sell as many as possible to investors. Such structures are common among smaller public companies seeking capital without the firm commitment typically required in larger underwritten deals.
Read more Petrus Challenges Tata Motors Offer Price for Iveco Group →
Bangkok-based NewGenIvf describes itself as a tech-forward, multi-jurisdictional entity with operations spanning real estate development, digital asset management, and reproductive health solutions. The company has positioned itself as a high-growth enterprise pursuing diversified revenue streams across distinct industries.
The $1.25 million target represents a relatively modest capital raise by public-market standards, reflecting the company's current scale. Net proceeds available to the company will be lower once placement agent commissions and administrative costs are accounted for, though the company did not disclose the specific fee structure or intended use of proceeds in its initial announcement.
Continue reading at GlobeNewswire - Industry News on Financial Services.
